多发性硬化症患者使用缓释苯丙胺的建议。
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
机构信息
Department of Neurology and Center for Clinical Neuroscience, Charles University, General Hospital, Prague, Czech Republic.
出版信息
CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.
Abstract
Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.
摘要
延迟释放型苯丙胺（苯丙胺 PR）是一种钾通道阻滞剂，可改善中枢神经系统脱髓鞘轴突上信号的传导。苯丙胺 PR 已被批准用于改善多发性硬化症患者的行走速度。本声明简要总结了苯丙胺 PR 的相关数据，并就该药物在临床实践中的实际应用、对治疗反应和患者管理的预测和评估提出了建议。
相似文献
1
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).多发性硬化症患者使用缓释苯丙胺的建议。
CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.
2
Sustained-release fampridine for symptomatic treatment of multiple sclerosis.用于多发性硬化症症状治疗的缓释氨吡啶
Ann Pharmacother. 2008 Oct;42(10):1458-65. doi: 10.1345/aph.1L028. Epub 2008 Sep 9.
3
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.氟苯丙胺在多发性硬化症中应用的药理学原理的历史概述。
Expert Rev Clin Pharmacol. 2012 Nov;5(6):649-65. doi: 10.1586/ecp.12.59. Epub 2012 Nov 13.
4
Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.缓释金刚烷胺可改善一部分多发性硬化症患者的步行能力。
Expert Rev Neurother. 2013 Dec;13(12):1309-17. doi: 10.1586/14737175.2013.859523.
5
[4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].[4-氨基吡啶（法吡拉定）。多发性硬化对症治疗的新尝试]
Nervenarzt. 2010 Feb;81(2):203-11. doi: 10.1007/s00115-009-2902-2.
6
Dalfampridine in multiple sclerosis.达氟吡啶治疗多发性硬化症。
Drugs Today (Barc). 2010 Sep;46(9):635-9. doi: 10.1358/dot.2010.46.9.1499027.
7
Sustained release oral fampridine in the treatment of multiple sclerosis.缓释口服法吡酯治疗多发性硬化症
Expert Opin Pharmacother. 2009 Aug;10(12):2025-35. doi: 10.1517/14656560903075994.
8
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.多发性硬化症的缓释金刚烷胺：行走模式的改变对改善步态有效。
Mult Scler. 2016 Oct;22(11):1463-1475. doi: 10.1177/1352458515622695. Epub 2016 Jan 13.
9
Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.预测多发性硬化症步态障碍患者对苯丙胺的反应性。
Eur J Neurol. 2019 Feb;26(2):281-289. doi: 10.1111/ene.13805. Epub 2018 Oct 7.
10
Sustained-release fampridine for multiple sclerosis.用于多发性硬化症的缓释金刚烷胺。
Expert Opin Investig Drugs. 2009 Jul;18(7):1013-24. doi: 10.1517/13543780903002082.
引用本文的文献
1
Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.电压门控钾通道在神经元功能、缺血耐受和神经变性的交汇点。
Transl Stroke Res. 2014 Feb;5(1):38-58. doi: 10.1007/s12975-013-0297-7. Epub 2013 Nov 19.
本文引用的文献
1
Status epilepticus associated with dalfampridine in a patient with multiple sclerosis.一名多发性硬化症患者中与达氟吡啶相关的癫痫持续状态。
J Neuropsychiatry Clin Neurosci. 2012 Fall;24(4):E47-8. doi: 10.1176/appi.neuropsych.11110338.
2
Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.缓释二甲苯丙胺在多发性硬化相关步行障碍中的应用。
Ther Adv Neurol Disord. 2012 Jul;5(4):199-204. doi: 10.1177/1756285612447091.
3
Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.25 英尺定时步行测试的最小临床重要差异：一项多发性硬化症患者随机对照试验的结果。
Curr Med Res Opin. 2012 Jan;28(1):49-56. doi: 10.1185/03007995.2011.639752. Epub 2011 Nov 23.
4
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.一项扩展释放型口服地夫可特治疗多发性硬化症的 3 期临床试验。
Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.
5
Outcome measurement in multiple sclerosis: detection of clinically relevant improvement.多发性硬化症的疗效评估：发现具有临床意义的改善。
Mult Scler. 2010 May;16(5):604-10. doi: 10.1177/1352458509359922. Epub 2010 Jan 19.
6
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.缓释口服法吡酯治疗多发性硬化症：一项随机、双盲、对照试验
Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.
7
Employment in multiple sclerosis. Exiting and re-entering the work force.多发性硬化症患者的就业。离开和重新进入劳动力市场。
J Neurol. 2008 Sep;255(9):1354-60. doi: 10.1007/s00415-008-0910-y. Epub 2008 Jul 17.
8
Dose comparison trial of sustained-release fampridine in multiple sclerosis.缓释氨吡啶在多发性硬化症中的剂量比较试验。
Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30.
9
Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.多发性硬化症患者对身体功能的认知：步态和视觉功能最为重要。
Mult Scler. 2008 Aug;14(7):988-91. doi: 10.1177/1352458508088916. Epub 2008 May 27.
10
Extended-release bupropion induced grand mal seizures.缓释安非他酮诱发全身性癫痫发作。
J Am Osteopath Assoc. 2007 Oct;107(10):441-2.
Zotero 插件